Loading...
Market
Which major pharmaceutical company will announce a partnership or acquisition related to IDH mutation treatments by the end of 2024?
2
Resolution / Starting Odds
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Official announcements or press releases from major pharmaceutical companies
Story
FDA Approves Servier's Voranigo for Grade 2 Gliomas with IDH Mutations
Aug 6, 2024, 09:19 PM
The U.S. Food and Drug Administration (FDA) has approved Servier's vorasidenib, branded as Voranigo, for the treatment of Grade 2 gliomas with IDH1 or IDH2 mutations. This marks the sixth approval for Servier in cancers with IDH mutations. The approval is based on evidence from the INDIGO trial led by Patrick Wen, MD, and researchers at Dana-Farber. Vorasidenib was originally developed by Cambridge, MA-based Agios Pharmaceuticals, which sold its oncology portfolio to French pharma Servier in December 2020 for $1.8 billion upfront, with potential regulatory milestones of $200 million plus royalties. The drug has shown significant improvement in progression-free survival for patients compared to placebo.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%